When US and European regulators acted in recent years to support the use of animal model alternatives for drug development, reactions were mixed. There is broad acknowledgement regarding the limitations of animal-based disease models and their inability to fully recapitulate human biological complexity, contributing to a high clinical failure rate, and so there was true excitement for the possibilities.
Lipid nanoparticles (LNPs) are one of the most significant advances in drug delivery in decades. But developing successful LNP formulations demands deep knowledge of their key building blocks: Lipids.
In the wake of several high-profile eye drop recalls, we look at the challenges of achieving sterility in ophthalmic products, the consequences of failing to do so, and how AbbVie Contract Manufacturing ensures product sterility and safety.
In this exclusive seventh annual nasal and inhalation eBook, Drug Development & Delivery highlights how these routes of administration are bringing new life to orphaned drugs and open new opportunities for treatment beyond pulmonary and respiratory diseases. We also explore the challenges of nose-to-brain delivery, next-generation propellants, overcoming the limitations of dry powder inhalers, and successful formulation strategies.
James A. Roszell, PhD, and Doreen McMorran demonstrate how this technology has demonstrated potential in the transdermal administration of glucagon-like peptide-1 (GLP-1) agonists and cannabinoid receptor type 1 (CB-1) antagonists, primarily targeting obesity management and other conditions requiring glucose regulation.
Catherine Hanley, VP, Head of Marketing and Corporate Communications, explains how the company has rebalanced its network and aligned around its core strengths in biologics and sterile fill/finish manufacturing.
Mitsubishi Gas Chemical (MGC) is a leading company in the field of oxygen barrier and absorbing polymers. Based on these technologies and experiences, MGC launched new multilayer plastic vial named OXYCAPT™ in 2019. It has achieved an excellent oxygen, carbon dioxide, ultraviolet (UV) barrier, high water vapor barrier, very low extractables, high pH stability, low protein adsorption, high transparency, high break resistance, easier disposability, lighter weight, etc.
HERMES PHARMA is the leading expert in developing and manufacturing user-friendly oral dosage forms. As a CDMO, we offer customized services along the entire pharmaceutical value chain, from new product development and formulation to manufacturing and regulatory support. For more than 40 years, healthcare companies around the globe have worked with HERMES PHARMA to expand their product lines and grow their brands.
Our sister company HERMES Arzneimittel has a rich portfolio of OTC brands and a long history in pharmaceutical excellence. So, we truly understand the challenges of our customers and can support them on their way to market success.
Late-stage surprises continue to drive cost, delay, and challenges in oral solid dosage (OSD) development—especially for complex, poorly soluble molecules. Too often, formulation and manufacturability risks surface only after significant time and investment.
In a recent panel discussion, GlobalData’s Director …
Bioabsorbable poly(lactide-co‑glycolide) (PLG) polymers and poly(lactic acid-co-glycolic acid) (PLGA) have become an essential part of modern healthcare. Over the past five decades, these polymers have transformed how medicines are delivered – enabling long-acting injectables, implants, and localized drug‑delivery products …
As drug development grows more complex and timelines compress, sponsors require CDMO relationships built on integration, flexibility, and shared accountability. The relationship between pharmaceutical sponsors and their CDMO partners has undergone a fundamental …
DRUG DEVELOPMENT DIRECT RESOURCES
Upcoming eNewsletter Features:
July 29 – Drug Delivery
August 5 – Injection Devices
August 12 – Lyophilization Manufacturing
August 19 – Excipients